Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Aequus Pharmaceuticals Inc. (V:AQS)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEDAR
Company Contact
Address: 2820 Granville St
VANCOUVER BC V6C 1S4
Tel: N/A
Website: www.aequuspharma.ca
IR: See website
Key People
Douglas Glen Janzen
Chairman of the Board, President, Chief Executive Officer
Ann Fehr
Chief Financial Officer
Anne Michelle Stevens
Vice President - Corporate Development, Executive Director, Secretary
Business Overview
Aequus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products. The Company operates through the segment of sales and marketing of pharmaceutical drugs developed by the Company or by its collaborative partners. Its products include tacrolimus immediate releaser, which is an immunosuppressive therapy used for the treatment and prevention of acute rejection following organ transplantation; Vistitan, which is a ophthalmology product; Topiramate extended-release (XR), which is a once-daily topiramate product designed for patient compliance, and Oxcarbazepine XR, which is a once-daily oxcarbazepine product. Its development-stage pipeline includes various products in neurology and psychiatry. Its lead development-stage product candidate is AQS-1301. In addition, the Company is developing a pipeline of other central nervous system product candidates. It has over two preclinical-stage programs and a clinical-stage program in development.
Financial Overview
For the nine months ended 30 September 2019, Aequus Pharmaceuticals Inc revenues decreased 6% to C$1.1M. Net loss decreased 3% to C$2.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and Development Expense - Balan decrease of 78% to C$67K (expense), General administration - Balancing value decrease of 15% to C$1.1M (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $11.70M as of Sep 30, 2019
Annual revenue (TTM): $1.33M as of Sep 30, 2019
EBITDA (TTM): -$2.47M as of Sep 30, 2019
Net annual income (TTM): -$2.74M as of Sep 30, 2019
Free cash flow (TTM): -$1.92M as of Sep 30, 2019
Net Debt Last Fiscal Year: $0.99M as of Sep 30, 2019
Shares outstanding: 80,437,970 as of Sep 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization